Myovant Sciences Ltd. (NYSE:MYOV)

Stock Price: $26.89
+0 (0%)
Updated Feb 2, 2023 09:00 PM GMT+0000
Featured app
eToro
Invest now
<p>79% of retail CFD accounts lose money</p>
Overview
Financials
Statistics
Profile
Chart
Market Cap 2.61B
Revenue 0
Gross Profit 0
Shares Out 97.24M
EPS (ttm)
PE Ratio 0.0000
Forward PE 0.0000
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Feb 2
Last Price $26.89
Previous Close $26.89
Change ($) 0
Change (%) 0%
Day's Open 26.89
Day's Range 26.845 - 26.9
Day's Volume 1.31M
52 Week Range 7.67 - 27.03

About Myovant Sciences Ltd.

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer.

Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis.

Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

News

Quick info

Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Website
myovant.com
Ticker Symbol
MYOV
Reporting Currency
USD